Fanregratinib clinical trials
Also written HMPL-453.
How each study uses fanregratinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fanregratinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HMPL-453
- 7
Studies by the year they started
8 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses fanregratinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- HMPL-453 Tartrate in Advanced Intrahepatic CholangiocarcinomaRecruitingPhase 2/3HutchmedNCT04353375Written as HMPL-453
- The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate TabletsCompletedPhase 1HutchmedNCT07697157Written as HMPL-453 with Itraconazole
- Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male SubjectsCompletedPhase 1HutchmedNCT07644442Written as HMPL-453
- A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid TumorsCompletedPhase 1/2Hutchison Medipharma LimitedNCT05173142Written as HMPL-453
- HMPL-453 Food Effect and PPI Study in Healthy Volunteer StudyCompletedPhase 1HutchmedNCT05930119Written as HMPL-453
- HMPL-453 in Advanced Malignant MesotheliomaStatus unknownPhase 2Hutchison Medipharma LimitedNCT04290325Written as HMPL-453
- A Study of HMPL-453 in Patients With Advanced Solid MalignanciesStatus unknownPhase 1/2Hutchison Medipharma LimitedNCT03160833Written as HMPL-453
- A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid MalignanciesTerminatedPhase 1Hutchison Medipharma LimitedNCT02966171Written as HMPL-453
Codes
What other systems call fanregratinib · ClinicalTrials.gg INT015714
- UNII (FDA) 8RWL2B2CLSFANREGRATINIBOne source FDA
- NCI Thesaurus C150383FanregratinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8RWL2B2CLS | FANREGRATINIB | One source FDA |
| NCI Thesaurus | C150383 | Fanregratinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.